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Abstract 
Epidemiological evidence suggests that low levels of vitamin D may predispose 
people to develop depression and cognitive impairment. While rodent studies have 
demonstrated that prenatal vitamin D deficiency is associated with altered brain 
development, there is a lack of research examining adult vitamin D (AVD) deficiency. 
The aim of this study was to examine the impact of AVD deficiency on behaviour and 
brain function in the mouse. Ten-week old male C57BL/6J and BALB/c mice were 
fed a control or vitamin D deficient diet for 10 weeks prior to, and during behavioural 
testing.  We assessed a broad range of behavioural domains, excitatory and 
inhibitory neurotransmission in brain tissue, and, in separate groups of mice, 
locomotor response to D-amphetamine and MK-801. Overall, AVD deficiency 
resulted in hyperlocomotion in a novel open field and reduced GAD65/67 levels in 
brain tissue. AVD-deficient BALB/c mice had altered behaviour on the elevated plus 
maze, altered responses to heat, sound and shock, and decreased levels of 
glutamate and glutamine, and increased levels of GABA and glycine. By contrast 
C57BL/6 mice had a more subtle phenotype with no further behavioural changes but 
significant elevations in serine, homovanillic acid and 5-hydroxyindoleacetic acid. 
Although the behavioural phenotype of AVD did not seem to model a specific 
disorder, the overall reduction in GAD65/67 levels associated with AVD deficiency 
may be relevant to a number of neuropsychiatric conditions. This is the first study to 
show an association between AVD deficiency and prominent changes in behaviour 
and brain neurochemistry in the mouse. 
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1. Introduction 
The role of vitamin D in adult brain function has attracted considerable attention in 
recent years [1]. Apart from the well-established role in calcium homeostasis, key 
features of the vitamin D system have been identified in the central nervous system. 
For example, the vitamin D receptor and the key enzyme required for its activation, 
25-OH D3 1α hydroxylase,  has been identified in both neuronal and glial cells in the 
human brain [2]. Vitamin D has been linked to key neurotrophic agents, such as 
nerve growth factor and glial cell-derived neurotrophic factor [3,4], and animal 
experiments have suggested that the active form of the vitamin has ‘neuroprotective’ 
features. For example, pre-treatment with vitamin D attenuates the effects of various 
stressors, including 6-hydroxydopamine-induced neurotoxicity [5,6]. Moreover, 
vitamin D deficiency in adult rats has been shown to exacerbate stroke injuries and 
lead to more severe post-stroke behavioural impairments and this was accompanied 
by lower levels of the neuroprotective hormone, insulin-like growth factor 1 [7]. 
Clues from epidemiology suggest that developmental vitamin D (DVD) deficiency 
may be associated with an increased risk of schizophrenia [8] and there has been 
considerable focus on animal models that examine the impact of DVD deficiency on 
brain related outcomes [9-11]. For example, rats exposed to DVD deficiency have 
decreased expression of nerve growth factor [4]. They also have ventricular 
enlargement as neonates [9] a finding that persists through to adulthood [4]. DVD 
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neonates have alterations in catechol-O-methyl transferase expression and 
dopamine metabolism [12] and early alterations in dopamine ontogeny [13]. Links 
between dopamine and vitamin D have also been identified in adult animals. Vitamin 
D has been shown to promote the synthesis of tyrosine hydroxylase, the rate-limiting 
enzyme of dopamine synthesis and also to increase basal levels of dopamine within 
the central nervous system after localised injection of vitamin D3 [6,14].   
The research community has become more aware of the role of vitamin D in adult 
brain function and epidemiological studies have examined links with various 
neuropsychiatric disorders. For example, cross-sectional studies have reported 
significant associations between low concentrations of 25-OH D3 in adults and 
various indicators of cognitive function, including memory and orientation [15-17], 
executive function [18,19], and diagnosis of dementia and Alzheimer’s disease [20]. 
A recent prospective study [21] found that baseline vitamin D deficiency was 
associated with greater impairment of cognitive tasks in subsequent years. However, 
other studies have not found an association between vitamin D status and brain 
outcomes [22-24].  
Studies on European populations have shown that second generation dark-skinned 
migrants (with a reduced ability to generate vitamin D from sunlight) have an 
increased risk of being diagnosed with schizophrenia compared to other immigrants 
and an even greater risk compared to the native born [25]. Vitamin D deficiency has 
been linked to a number of other neurological disorders including autism [26], 
seasonal affective disorder [27,28], and multiple sclerosis [29]. Cross-sectional 
studies have reported an association between vitamin D status and depressive 
symptoms [30]. A prospective study reported that women with low levels of vitamin D 
at baseline reported higher levels of depressive symptoms 3 and 6 years later [31]. 
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To date, there has only been one study to investigate the impact of AVD deficiency 
on brain function and behaviour in rodents [32]. However, in that study the Sprague-
Dawley rats were fed a vitamin D deficient diet from weaning and they had reduced 
body weight compared to controls, which suggests that musculoskeletal problems 
may have confounded interpretation of behavioural outcomes in the study. AVD 
deficiency has previously been associated with altered catecholamine metabolism in 
the cortex of Sprague-Dawley rats, with alterations in the levels of noradrenaline and 
dihydroxyphenylacetic acid, a breakdown product of dopamine [33]. However, there 
was no behavioural data reported. Thus, to our knowledge there are no published 
data on the impact of AVD deficiency on mouse behaviour or brain function and thus 
it is difficult to predict how this may impact on different behavioural domains or brain 
neurochemistry in mice.  
The aim of this study was to establish a model of AVD deficiency in two strains of 
mice and to examine a broad range of behavioural tests and selected neurochemical 
outcomes within the brain. BALB/c and C57BL/6J strains were chosen for this study 
because they are inbred strains that are commonly used in biomedical research, and 
show markedly different behavioural phenotypes [34]. The overarching aim of this 
work was to establish a model of adult vitamin D deficiency, rather than model a 
single neuropsychiatric disorder. Indeed, a recent review highlighted the fact that 
vitamin D deficiency is associated with a range of neuropsychiatric outcomes [11]. 
As such we used a multi-tiered behavioural test battery to broadly assess the 
behavioural domains of locomotion, exploration, anxiety, social behaviour, learned 
helplessness, sensorimotor gating, associative learning, and nociception, as well as 
responses to the psychomimetic agents D-amphetamine and MK-801. These 
behavioural tasks are relevant to a number of neuropsychiatric disorders including 
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pyschosis, schizophrenia, anxiety and depression. Neurochemical profiles were 
analysed in drug-naïve mice in order to explore the effect of AVD deficiency on 
levels of catecholamines and amino acids, as well as selected enzymes involved 
with key neurotransmitters.  
2. Materials and Methods 
2.1 Animals and housing 
A total of 148 male mice were used in this study (79 x C57BL/6J and 69 x BALB/c). 
Ten week old C57BL/6J and BALB/c mice (Animal Resources Centre, Canning Vale, 
WA, Australia) were obtained and housed in groups of 4 in individually ventilated 
cages (Techniplast, VA, Italy), with corn cob bedding (Shepherd Specialty Papers, 
Inc., TN, USA) at the Eskitis Animal House Facility, Griffith University. The mice were 
assigned to either a control diet (Standard AIN93G Rodent diet with 1,000 IU vitamin 
D3/kg, Specialty Feeds, WA, Australia) or a vitamin D-deficient diet (Vitamin D3 
Deficient AIN93G Rodent diet, Specialty Feeds, WA, Australia) for a minimum of 10 
weeks prior to the start of behavioural testing; and for the entire duration of the 
experimental procedures. The mice were maintained on a 12-hour light-dark cycle 
(lights on at 07:00 h) with ad libitum access to food and water. They were housed 
under incandescent lighting free from UVB radiation. All experimental work was 
performed with approval from the Griffith University Animal Ethics Committee, under 
the guidelines of the National Health and Medical Research Council of Australia. 
2.2 Procedure 
Behavioural phenotyping began when the on postnatal day 140 (P140). Mice were 
exposed to a variety of tests assessing various behavioural domains. The tests were 
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performed on separate days and in the following order (approximate age of mice at 
each test); open field (P140), elevated plus maze (P168), holeboard (P169), 
light/dark test (P170), forced swim test (P171),  prepulse inhibition of the acoustic 
startle response (P175), active avoidance (P182), social interaction (P189), hot plate 
test (P196). Sixteen C57BL/6J mice (n = 8/diet) and sixteen BALB/c mice (n = 8/diet) 
were subjected to the behavioural test battery, with additional mice from each strain 
tested in the novel open field (n = 28/diet/strain), ASR, and PPI of ASR (n = 
20/diet/strain). Behaviours were recorded by two methods, either by video recording 
software (Miglia TV, Hertfordshire, UK) or a USB webcam and recording software 
(Media Player) and analysed by computer tracking software (Ethovision, Noldus, 
Wageningen, The Netherlands). All apparatus was cleaned before and after each 
mouse with 80% ethanol. 
2.2.1 Open Field 
The open field test was used to measure baseline locomotion [35]. The open field 
apparatus was an opaque box (28 cm high x 30 cm x 30 cm), in which the mice were 
placed in the centre of the arena. The test lasted for 30 min, during which time both 
total distance travelled and distance travelled over time were analysed to assess 
locomotion. Locomotion was assessed in a novel environment, and also in a familiar 
environment, with a subset of mice (n=9-10 per group) re-exposed to the same open 
field arena 7 weeks later. 
2.2.2 Elevated plus maze 
The elevated plus maze was used to measure anxiety-related behaviour [36]. The 
elevated plus maze was made of opaque grey acrylic, and was attached to a stand, 
raising it 50 cm off the ground. It was comprised of four arms (each 5 cm x 30 cm) 
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radiating out from a centre platform (5 cm x 5 cm) in the shape of a plus. Two 
opposing arms had sides (closed arms) and the other two did not (open arms). Mice 
were placed on the centre platform, facing out towards one of the open arms, with 
the test lasting for 10 min. The main parameter tested was the time spent on the 
open arms compared to the time spent on the closed arms. The total distance 
travelled in the 10 min test was also analysed. 
2.2.3 Holeboard Test 
The holeboard test was used to measure exploration based on the frequency of 
head-dipping into small holes situated in the floor of an open field [37]. A white 
acrylic base containing four evenly spaced holes (2.5 cm diameter), was added to 
the bottom of a black box (30 cm high x 30 cm x 30 cm) to create the holeboard. The 
mice were initially placed along the edge of the wall and the number of head-dips in 
a 10 min period was analysed, along with the total distance travelled. 
2.2.4 Light/dark test 
The light/dark test was used in the behavioural test battery to aid in the analysis of 
anxiety levels of the mice [38]. The two-chambered light/dark apparatus consisted of 
an open black box (30 cm high x 30 cm x 30 cm), with half of the box containing a 
black insert (15 cm high x 30 cm x 15 cm) creating the dark chamber. The insert had 
a small rounded open doorway in the centre leading to the light chamber. The mice 
were placed in the doorway with their head inside the dark chamber and two main 
parameters were analysed. The time for the mouse to emerge from the dark chamber 
into the light and the percentage of time the mouse spent in the light chamber in a 10 
min period. 
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2.2.5 Forced swim test 
The forced swim test was used to measure learned helplessness [39]. The apparatus 
used in the forced swim test was a clear round container (20 cm high x 13 cm 
diameter) with a column of water (16 cm deep) maintained at 25 °C, from which the 
mouse could not escape. The percentage of time the mouse spent immobile in each 
one min time bin, over a 10 min period was the parameter analysed.  
2.2.6 Prepulse inhibition of the acoustic startle response 
PPI of the ASR was used to measure sensorimotor gating [40] using startle 
chambers (SR-Lab, San Diego Instruments, CA, USA), which consisted of a 
Plexiglass cylinder (5 cm diameter x 12 cm long) mounted on an elevated Plexiglass 
base within a dark chamber. A speaker situated 24 cm above the cylinder was used 
to provide background noise within the chamber set to 70 dB as well as the acoustic 
pulses of white noise throughout the testing. 
Testing began with an acclimatisation period of 300 s of 70 dB background noise. 
The mice then underwent a total of 130 trials (26 different blocks of 5 trials). To 
assess within-trial habituation, startling pulses of 110 dB were presented at the start 
(post acclimatisation), middle and end of the testing. The mice were exposed to a 
range of pulse intensities (80, 90, 100, 110 and 120 dB) to measure ASR and a 
range of prepulse to pulse intervals (8, 16, 32, 64, 128 and 256 ms) before a 120 dB 
pulse to measure PPI. The median values for each block of 5 trials were used for 
analysis, with PPI being calculated with the formula: %PPI = [(startle amplitude of 
ASR trial - startle amplitude on prepulse trial)/startle amplitude of ASR trial] x 100. 
2.2.7 Active avoidance 
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The active avoidance test was used to measure associative learning, using a 
conditioned avoidance response [41]. The active avoidance chambers (Gemini, CA, 
USA) consisted of two compartments (18 cm high x 26 cm x 21 cm) separated by a 
guillotine door (10 cm high x 7 cm) above a barrier. Testing began with a 300 s 
acclimatisation period followed by 80 trials. Each trial was comprised of a 4 s 
conditioned stimulus, followed by a 16 s unconditioned stimulus. The conditioned 
stimulus consisted of a tone, cue light and the opening of the door and the 
unconditioned stimulus consisted of a 0.4 mA shock delivered to the floor. The door 
between the chambers remained open during the trial until the mouse moved 
through it to the other compartment. Each trial was separated by a 20 s inter-trial 
interval with no stimulus, with the door between compartments closed.  
Active avoidance for each mouse was analysed over 3 consecutive days. The first 
two days followed the above method for acquisition and retention; with the third day, 
a test of extinction, in which the unconditioned stimulus was removed. Each trial still 
began with the 4 s conditioned stimulus, but was followed by 16 s with no stimulus, 
in order to test the mouse’s ability to learn a new response to the original conditioned 
stimulus. 
2.2.8 Social interaction test 
The social interaction test was used to measure the behavioural responses of two 
unfamiliar, diet and weight matched mice to each other [42]. The test was conducted 
in an open field arena and behaviours were analysed over a 10 min period. A variety 
of behaviours were assessed including sniffing, self-grooming, allo-grooming, 
following and rearing. 
2.2.9 Hot plate test 
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The hot plate test was used to measure a response to noxious stimuli [43]. The hot 
plate (Harvard Apparatus, Ltd., Kent, England) was maintained at 53 °C, with the 
mice contained on the hot plate within a clear Perspex cylinder (27 cm high x 20 cm 
diameter). The test consisted of three trials, of a maximum length of 30 s. The 
parameter measured was the latency to lick hind paw or to jump with both feet, in an 
attempt to escape. The mouse was removed immediately after this was achieved. If 
this was not achieved by the end of the 30 s, the mouse was removed and the trial 
ended. The inter-trial period was 60 s. 
2.3 Brain Neurochemistry 
2.3.1 Tissue Collection 
Body weight was monitored on a fortnightly basis throughout the study for all mice. 
At the time on euthanasia, body measurements were taken from both strains of 
mice, for body length (from tip to snout to base of tail) and tail (from base to tip). 
Brains were collected from drug-naïve mice subjected to the behavioural test battery. 
Mice were euthanized by carbon dioxide followed by decapitation. The whole brain 
was removed and weighed. Using free-hand dissection, each brain was sectioned 
into left and right cerebrum and hindbrain, with olfactory bulbs removed. Tissue was 
frozen on dry ice and stored at -80 C until further processing. 
2.3.2 High performance liquid chromatography and analysis 
Catecholamines and amino acids from brain tissue were measured by high 
performance liquid chromatography with electrochemical and fluorescent detection 
using a standard protocol. Data was stored and processed with ChemStation 
software (B1.03.02, Agilent Technologies, Inc., CA, USA). Data was quantified by 
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calculating peak-area ratios of each compound compared to deoxyepinephrine 
(catecholamine internal standard) or homoserine (amino acid internal standard) and 
corrected for dilution. Identity of each compound was determined by retention time 
and the final amount was expressed as nanogram per gram (ng/g) wet tissue. 
2.3.3 Protein analysis 
Brain tissue was analysed for protein content using western analysis. Total protein 
was collected by sonication in 20 mM Hepes, 1 mM EDTA lysis buffer (pH 7.4) 
containing 1% Triton and 1X Protease Inhibitor cocktail (Sigma). Following 
centrifugation, protein concentrations in the supernatant were determined using a 
BCA protein assay (Pierce, Rockford, IL, USA). Between 15 and 30 g of protein 
was loaded for all samples dependent on protein to be analysed. Proteins were 
separated by standard polyacrylamide gel electrophoresis techniques on 4-12% Bis-
Tris SDS-PAGE gels. Separated proteins were transferred to Immobilon-FL 
membranes (Millipore, Bedford, MA, USA) at 0.4 A for 2 h at room temperature. 
Membranes were blocked in Lycor Odyssey Blocking buffer (Millenium Science, VIC, 
Australia) for 1 h and incubated with primary antibodies for 1 h at room temperature 
or overnight at 4 C in Lycor Odyssey blocking buffer. The primary antibody dilutions 
were as follows: catechol-O-methyl transferase, monoclonal mouse anti-mouse 
antibody (BD Biosciences, San Jose, CA, USA) 1:2000; monoamine oxidase A, 
polyclonal rabbit anti-human antibody (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) 1:2000; glutamine synthetase, polyclonal rabbit anti-human antibody (Abcam, 
Cambridge, UK) 1:12,000; GAD 65/67, polyclonal rabbit anti-human antibody 
(Sigma-Aldrich, St Louis, MO, USA) 1:150,000; and the normalising gene 
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glyceraldehyde-3-phosphate dehydrogenase, monoclonal mouse anti-rabbit antibody 
(Millipore, Bedford, MA, USA) 1:100,000). 
The membranes were then washed in phosphate buffered saline with 1% Tween 20 
for 3x 10 min and exposed to secondary antibodies conjugated with IRDyes for 1 h 
at room temperature. The IRDye 800CW-polyclonal goat anti-rabbit antibody 
(Millenium Science, VIC, Australia) was diluted 1:15,000 for binding to monoamine 
oxidase A antibodies and 1:30,000 for binding to GAD65/67 antibodies. The IRDye 
680-polyclonal goat anti-mouse antibody (Millenium Science, VIC, Australia) was 
diluted 1:20,000. The membranes were again washed in phosphate buffered saline 
with 1% Tween 20 for 3x 10 min and the protein bands visualized on a Licor 
Odyssey CLx scanner. Amount of proteins were normalised against glyceraldehyde-
3-phosphate dehydrogenase. 
2.4 Behavioural Pharmacology 
The open field arena was used to assess behaviour in response to two 
psychomimetic drugs in separate groups of mice. Mice were habituated to the open 
field for 30 min before receiving an intra-peritoneal injection of a 4 ml/kg 0.9 % saline 
solution. They were placed back in the open field for a further 30 min following this 
injection (Data not shown). They then received an intra-peritoneal injection of a 4 
ml/kg solution of either D-amphetamine (control n=9, AVD n=10) or MK-801 (control 
n=8, AVD n=8). They were placed back in the open field and their behaviour was 
recorded for up to 210 min. 
2.4.1 Psychomimetic Drugs 
D-amphetamine (Sigma, MO, USA) was diluted to a concentration of 1.25 mg/ml in 
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0.9 % saline solution and aliquots were stored at -20 °C. Mice were given an 
injection dose of 5 mg/kg. MK-801 (Sigma, MO, USA) was diluted to a concentration 
of 0.125 mg/ml in 0.9 % saline solution and aliquots were stored at -20 °C. Mice 
were given an injection dose of 0.5 mg/kg. The drug dosage used was based on 
previous studies showing a high locomotor response with little stereotypic or ataxic 
behaviours [44,45]. 
2.5 Blood chemistry 
At the completion of experimental procedures, a terminal blood sample was taken 
from each mouse via cardiac puncture. The levels of 25-OH D3 was measured in 
serum samples using liquid chromatography-tandem mass spectrometry (Sciex 
Instruments, ON, Canada) on a 4000 QTrap API AB mass spectrometer [46]. BALB/c 
control: 32.0 ± 1.7 nM, AVD-deficient: 2.9 ± 0.2 nM, and C57BL/6J control: 65.3± 2.3 
nM, AVD-deficient: 2.9 ± 0.1 nM. 
Calcium levels (n=17-19) were measured in serum samples using the QuantiChrom 
Assay Kit using quantitative colormetric determination (BioAssay Systems, CA, USA) 
and were not significantly different between groups. BALB/c control: 2.33 ± 0.15 mM, 
AVD-deficient: 2.20 ± 0.09 mM, C57BL/6J control: 2.28 ± 0.09 mM, AVD-deficient: 
2.13 ± 0.10 mM).  
2.6 Statistical analysis 
Results were analysed for statistical significance using SPSS (version 17.0) 
software. All data were analysed for the main effects of Diet (control or AVD-
deficient) and Strain (C57BL/6J or BALB/c) using analysis of variance (ANOVA) or, 
where appropriate, repeated measures ANOVA. Mann-whitney U test was used to 
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analyse non-parametric data. Significant differences (p<0.05) were followed up with 
post-hoc t-tests. 
3. Results 
3.1.1 Open Field 
The locomotor response was measured both in a novel environment and in a familiar 
environment. Overall, AVD-deficient mice from both strains exhibited increased 
locomotion compared to the controls in a novel environment (F1,108 = 11.18, p = 
0.001) (Fig.1a and b). There was a significant effect of Diet in both BALB/c (F1,54 = 
4.13, p = 0.047) and C57BL/6J mice (F1,54 = 9.11, p = 0.004). Repeated measures 
ANOVA indicated that mice were significantly less active when subsequently tested 
under familiar conditions, compared with activity levels under novel conditions (F1,34 
=21.1, p < 0.001).  However, there was a significant Strain x Diet interaction on the 
locomotor  response in the familiar environment (F1,34 =6.5, p < 0.05); the AVD-
deficient BALB/c mice showed a significant reduction in locomotion compared with 
control BALB/c mice (F1,17 = 8.66, p = 0.009), while there was no significant effect of 
Diet in the C57BL/6J mice (F1,17 = 1.42, p = 0.250) (Fig.1c and d). 
<<Insert Fig. 1 about here>> 
 3.1.2 Elevated plus maze 
On the elevated plus maze, all mice entered the closed arms and all but two control 
mice entered the open arms at least once. There was a significant effect of Diet on 
the time spent on the open arms for the BALB/c mice (F1,14 = 14.57, p = 0.002). 
Compared to controls, the BALB/c AVD-deficient mice spent a significantly longer 
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time on the open arms (Fig. 2a and b).  There was no significant effect of Diet for the 
C57BL/6J mice (F1,14 = 0.43, p = 0.839). There was a significant main effect of Strain 
(F1,28 = 10.07, p = 0.004) on the distance travelled while on the elevated plus maze 
with C57BL/6J mice travelling further than the BALB/c mice, however, there was no 
significant effect of Diet on total distance travelled.  
<<Insert Fig. 2 about here>> 
3.1.3 Holeboard test 
In the holeboard test, all mice poked their noses into the holes. There was a 
significant main effect of Strain on the frequency of head-dipping (F1,28 = 5.12, p = 
0.032) as well as on the latency to groom (F1,28 = 4.26, p = 0.048) and the total 
distance travelled (F1,28 = 20.71, p = <0.001). However, there was no significant effect 
of Diet on any measure on the holeboard test. 
3.1.4 Light/dark test 
All mice entered the light chamber at least once during the test. There was no 
significant effect of Diet or Strain on the time to emerge, however, there was a 
significant effect of Strain on the frequency to enter the light chamber (F1,28 = 22.89, p 
<0.001). There was no effect of Diet on any measure on the light/dark test. 
3.1.5 Forced swim test 
All mice became increasingly immobile over the course of the forced swim test. There 
was no significant difference in the time spent immobile between diet groups from 
either strain. However, there was a significant effect of Strain (F1,28 = 417.48, p 
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<0.001) with the BALB/c mice spending a greater amount of time immobile than the 
C57BL/6J mice.  
3.1.6 Prepulse inhibition of the acoustic startle response 
All mice responded to increasing pulse amplitude with increased startle response. 
There was a significant interaction of Diet x Strain (F1,75 = 5.93, p = 0.017). Although 
there was no significant effect of Diet on the ASR of C57BL/6J mice (F1,38 = 0.03, p = 
0.874), there was a significant effect of Diet for the BALB/c mice (F1,37 = 23.52, p 
<0.001) with AVD-deficient mice showing an enhanced startle response compared to 
controls (Fig. 2c and d). There was no significant main effect of Diet (F1,75 = 0.08, p = 
0.785)  or Strain (F1,75 = 0.55, p = 0.459)  on PPI scores.  
3.1.7 Active avoidance 
Mice of each strain responded quite differently to the test of avoidance learning and 
some of the BALB/c mice had difficulty learning the avoidance paradigm all together. 
There was a significant Diet x Strain interaction for acquisition of learning (Day 1) 
(F1,28 = 4.63, p = 0.040). There was no significant effect of Diet on the latency to 
escape in C57BL/6J mice but there was a significant effect of Diet on the latency to 
escape for BALB/c mice during acquisition (F1,14 = 6.44, p = 0.024) (Fig. 3a and b). 
This difference did not reach significance on Day 2, for retention (F1,14 = 4.12, p = 
0.062) or on Day 3, for the extinction trial (F1,30 = 1.07, p = 0.310).  
There was no significant effect of Diet for the C57BL/6J mice on any of the response 
scores (avoid, escape or no response) on Day 1 or over the 3-day test. There was a 
significant effect of Diet (F1,14 = 6.62, p = 0.022) for the BALB/c mice on the no 
response score on Day 1 of the test; the AVD-deficient mice made fewer no response 
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scores than the controls. The effect of Diet on the no response score over the 3-day 
test did not reach significance (F1,30 = 4.05, p = 0.053). 
3.1.8 Social interaction test 
In the social interaction test there was no significant effect of Diet on either strain for 
any measure analysed. There were significant effects of Strain for following (F1,25 = 
29.82, p <0.001) and rearing (F1,25 = 60.63, p <0.001) with BALB/c mice having 
reduced following and rearing compared to the C57BL/6J mice.  
3.1.9 Hot plate test 
On the first trial of the hot plate test, there was a significant main effect of Strain 
(F1,28 = 51.02, p <0.001) but not of Diet: the C57BL/6J mice had a shorter latency to 
lick the hindpaw than the BALB/c mice. When analysing the BALB/c mice separately, 
there was a significant effect of Diet on the first trial (U14 = 16, p = 0.0325) with all the 
control BALB/c mice being removed from the hot plate at the end of the trial (30 s), 
because none of them licked their hind paw in response to the heat stimulus. 
When analysing the average response over three trials, there was a significant main 
effect of Strain (F1,28 = 72.72, p <0.001) and also a significant main effect of Diet (F1,28 
= 10.12, p = 0.004) with no Strain x Diet interaction. When analysing the strains 
separately, there was a significant effect of Diet (F1,14 = 7.86, p = 0.014) in the 
BALB/c strain but not in the C57BL/6J mice (F1,14 = 3.46, p = 0.084), the BALB/c 
AVD-deficient mice had a shorter latency to lick the hind paw compared to the control 
BALB/c mice (Fig. 3c and d).  
<<Insert Fig. 3 about here>> 
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3.2 Brain Neurochemistry 
Analysis of the neurotransmitter and metabolite levels from brain tissue indicated a 
significant effect of Strain on levels of noradrenaline (F1,28 = 27.05, p = <0.001), 5-
hydroxyindoleacetic acid (F1,28 = 22.62, p = <0.001), 3-methoxytyramine (F1,28 = 
12.60, p = 0.001), serine (F1,28 = 16.45, p = <0.001), glycine (F1,28 = 200.54, p = 
<0.001), tyrosine (F1,28 = 12.65, p = 0.001), GABA (F1,28 = 65.02, p = <0.001), and 
methionine (F1,28 = 6.15, p = 0.019). 
When analysing the BALB/c strain separately, there was a significant effect of Diet 
on the levels of glutamine (F1,14 = 4.98, p = 0.043), glutamate (F1,14 = 6.69, p = 
0.022), glycine (F1,14 = 6.24, p = 0.026) and GABA (F1,14 = 5.90, p = 0.029). 
Glutamine and glutamate levels were significantly lower in the AVD-deficient mice, 
whereas levels of glycine, lysine, and GABA were significantly higher in the AVD-
deficient mice (Table 1). 
There was a significant effect of Diet on the levels of 5-hydroxyindoleacetic acid 
(F1,14 = 12.97, p = 0.003), homovanillic acid (F1,14 = 4.69, p = 0.048), and serine (F1,14 
= 28.04, p = 0.000) in C57BL/6J mice. The levels of all three were higher in the AVD-
deficient mice (Table 1). The ratio of 5-hydroxytryptamine to 5-hydroxyindoleacetic 
acid was significantly altered (F1,14 = 9.16, p = 0.009) as was the ratio of dopamine to 
homovanillic acid (F1,14 = 8.34, p = 0.012). A summary of all the significant effects of 
Diet are found in Table 2. 
<<Insert Table 1 about here>> 
3.3 Protein analysis 
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GAD65/67 content showed a significant main effect of Diet (F1,28 = 6.41, p = 0.017) 
and of Strain (F1,28 = 38.17, p < 0.001) with no Strain x Diet interaction. The levels of 
GAD65/67 were lower in the AVD-deficient mice from both strains when compared to 
controls (Fig. 4).  
There was no significant effect of Diet on levels of catechol-O-methyl transferase 
(F1,27 = 0.12, p = 0.734), monoamine oxidase A (F1,27 = 3.25, p = 0.083) or glutamine 
synthetase (F1,28 = 0.38, p = 0.544) in the brain of either strain (data not shown).  
<<Insert Fig. 4 about here>> 
<<Insert Table 2 about here>> 
3.4 Behavioural Pharmacology 
As expected, locomotion was greatly increased by acute treatment with either 
amphetamine or MK-801. There was no significant main effect of Diet on the 
locomotor response to D-amphetamine (F1,34 = 0.002, p = 0.965) but there was a 
significant effect of Strain (F1,34 = 17.39, p = <0.001), with the C57BL/6J mice 
showing greater amphetamine-induced locomotion than the BALB/c mice (Fig. 5a 
and b). There was no significant main effect of Diet (F1,28 = 0.99, p = 0.329) or Strain 
(F1,28 = 2.65, p = 0.115) on the locomotor response to MK-801 (Fig. 5c and d). 
<<Insert Fig. 5 about here>> 
 
4. Discussion 
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The main outcomes of this study were that vitamin D deficiency in adult mice 
enhanced locomotion and produced a small reduction in the enzymes involved in 
GABA synthesis (GAD65/67). However, many other behavioural and neurochemical 
alterations were dependent on the background strain. The AVD-deficient BALB/c 
mice displayed altered behaviour on the elevated plus maze, and an enhanced 
response to aversive stimuli that included shock, heat and sound. This was 
accompanied by alterations in amino acid metabolism within the brain. AVD-deficient 
C57BL/6J mice had a more subtle behavioural phenotype, and a neurochemical 
profile with changes in dopamine and 5-hydroxytryptamine turnover.  
Spontaneous hyperlocomotion in a novel open field has been consistently observed 
in other rodent models of vitamin D deficiency, although these have been prenatal 
exposures. For example, 129/SvJ DVD-deficient mice exhibited spontaneous 
hyperlocomotion in the open field, and 129/SvJ and C57BL/6J DVD-deficient mice 
were hyper-explorative on the hole-board test [40]. Adult DVD deficient rats are more 
active than controls in novel environments [47,48], show an increased 
psychomimetic-induced hyperlocomotion and an enhanced startle response after 
MK-801 injection [49,50]. This suggests that the absence of vitamin D may lead to 
alterations in similar neural circuits in both the developing and adult brain.  
With respect to schizophrenia, the AVD mice did not replicate behavioural features 
typically seen in other animal models of schizophrenia. For example, two prominent 
features include deficits in PPI [51] and enhanced locomotor response to 
amphetamine [49]. These features are both based on alterations in dopamine 
metabolism, with the dopaminergic system being strongly implicated in the 
development of schizophrenia [52]. Moreover, although DVD-deficient rats show 
enhanced MK-801 induced locomotion [48,50] this was not seen in DVD-deficient 
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129/SvJ or C57BL/6J mice [45] or in AVD-deficient BALB/c or C57BL/6J mice in the 
current study. 
However, the AVD-deficient BALB/c mice had alterations in glutamate and glutamine 
levels in brain tissue, which may indicate a disruption in glutamatergic 
neurotransmission. There is mounting evidence to suggest that NMDA receptor 
dysfunction may contribute to schizophrenia symptoms, particularly those that are 
not relieved by antipsychotics. This dysfunction may be related more to the negative 
and cognitive symptoms of schizophrenia [53]. It has also been suggested that non-
NMDA receptor dysregulation may be involved in schizophrenia [54]. While the 
alterations in glutamate metabolism seen in the AVD-deficient BALB/C mice did not 
translate into known behavioural features of schizophrenia, this does not rule out the 
relevance these mice might have in schizophrenia research and for other 
neurological disorders, such as anxiety. 
The underlying neurobiological mechanisms of the behaviour of AVD deficient mice 
remain to be clarified. Despite a consistent decrease in GAD65/67 levels in both 
strains of mice used in this study, there was little overlap between strains for 
changes seen in brain neurochemistry. The small but significant reduction in 
GAD65/67 levels may be highly relevant to psychiatric conditions in which altered 
GABAergic neurotransmission has been implicated, including schizophrenia [55], 
autism [56], anxiety [57], depression [58], bipolar disorder [57,59] and obsessive 
compulsive disorder [57,60]. For example, reductions in GAD67 in parietal cortex 
and GAD65 in cerebellum were shown in post mortem brain tissue from autistic 
patients when compared to controls [61]. Another study reported global reductions in 
levels of GAD65/67 in the cerebella of subjects with schizophrenia, bipolar disorder 
and major depression [59]. Despite reports of small global reductions in GAD 65/67 
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these changes were shown to be accounted for by alterations in distinct 
subpopulations of neurons, including the larger-sized GABAergic dentate cells within 
the cerebellum [62]. In the current study subtle variations in specific brain regions or 
cell populations could not be detected as all analyses were performed on whole 
brain homogenates. Future studies would need to investigate localised changes in 
defined cell populations. 
The two strains used in this study differed on a range of physiological parameters, 
behavioural responses, and drug-induced behaviours, as well as in levels of several 
neurochemicals. The non-emotional, high locomotor C57Bl/6 strain showed very little 
effect of AVD deficiency except spontaneous hyperlocomotion, while the highly 
emotional, neophobic BALB/c strain showed significant effects of AVD deficiency, 
particularly involving limbic system functions. One of the major differences found 
between BALB/c and C57Bl/6 mice is the strong defensive behaviour the BALB/c 
mice show in response to unfamiliar places (neophobia). This is proposed as ‘trait’ 
anxiety, a stable characteristic of behaviour. Administration of benzodiazepines is 
able to abolish neophobia in BALB/c mice, whereas several other anxiolytic 
compounds cannot. Benzodiazepines are also devoid of anxiolytic effects in C57Bl/6 
mice [63]. The BALB/c strain shows a significant reduction in benzodiazepine 
receptor density compared to the C57Bl/6 strain [64]. This may at least in part 
explain the genetically determined predisposition to anxiety seen in the BALB/c mice. 
There was a 50% reduction in 25-OH D3 levels in control BALB/c mice compared to 
control C57BL/6 mice. Although AVD resulted in 25-OH D3 levels at the lower limit of 
detection, we suggest that there may be underlying differences in vitamin D 
metabolism between the two strains. For example, BALB/c mice have a 17-fold 
reduction in the levels of 1αOHase within the kidney compared to C57BL/6J mice 
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[65], which reduces the availability of active 1,25 dihydroxyvitamin D3 in the BALB/c 
strain. Moreover, wide variation in basal 25(OH)D levels have been reported in 18 
inbred mouse strains [66], the highest values were obtained in C57BL/6J (62.5 
nmol/L), with reduced amounts in all other strains examined, for example EVB/J (55 
nmol/L) C3H/HeJ (43 nmol/L), BALB/cJ (42 nmol/L), DBA/2J (37 nmol/L), to the 
lowest SJL/J (35 nmol/L). These values are consistent with those reported in our 
study; C57Bl/6J (65.3 nmol/L) and BALB/cJ (32.0 nmol/L). Therefore, the BALB/c 
strain may be genetically vulnerable to vitamin D deficiency, which could explain why 
they show a greater effect of the vitamin D deficiency both on behaviour and brain 
function. However, there are, as yet, no systematic reports in the literature 
correlating behavioural endophenotypes and basal vitamin D levels in multiple inbred 
mouse strains. It may be that animals with chronic insufficiency (such as the BALB/c 
strain) are more prone to develop behavioural disorders if they are exposed to a 
period of vitamin D deficiency. These studies may be a valuable area of future 
research. 
The biological consequences of relatively small changes in neurotransmitter levels 
remains to be established. However, we found significant strain differences in the 
effect of AVD deficiency on catecholamine, indolamine and amino acid levels, with a 
predominantly catecholamine/indolamine phenotype in C57BL/6 mice and a 
predominantly amino acid phenotype in BALB/c mice. There is significant variation 
between C57BL/6 and BALB/c mice on metabolic protein levels in brain tissue. For 
example, differences were shown for nucleic acid, amino acid and carbohydrate 
metabolism in proteomic analysis of hippocampal tissue from these strains of mice 
[67]. Strain dependent regulation of amino acid metabolism could explain why AVD-
deficiency had a greater impact on GABAergic and glutamatergic neurotransmitter 
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systems in BALB/c mice. With respect to indolamine levels (5-HT and 5-HIAA) 
C57BL/6 mice have approximately 50% higher rates of 5-HT synthesis than BALB/c 
mice because of a single nucleotide polymorphism in the mTph2 gene (C1473G) 
[68], which may lead to a greater vulnerability in AVD-deficient C57BL/6 mice when 
compared with BALB/c mice.  
The AVD-deficient BALB/c mice had a small increase in the levels of GABA and 
glycine, and decreased levels of glutamate and glutamine in brain tissue. GABA is 
the major inhibitory neurotransmitter in the brain and it is synthesised from glutamate 
by two isoforms of GAD; GAD65 and GAD67. Reduced levels of GAD65/67 are 
typically associated with a reduction in GABA synthesis. However, we observed an 
increase in GABA levels in AVD-deficient BALB/c mice and, despite a similar 
reduction in GAD65/67 levels in C57BL/6 mice, there were no significant changes to 
either glutamate or GABA levels in this strain. The mechanism/s by which vitamin D 
deficiency could lead to increases in GABA are unknown. However, recent studies in 
developing zebrafish indicate that the active metabolite of vitamin D affects a wide 
range of genes, including those involved with amino acid metabolism [69], although 
similar studies have not been carried out in rodents. It was shown that GAD65 KO 
mice maintain normal levels of GABA content in brain [70] and the overall reduction 
in GAD enzymes may signify a reduced conversion of glutamate to GABA, but 
differences in biochemical alterations following a reduction in GAD65/67 may vary 
between BALB/c and C57BL/6 mice. 
Positive modulators of GABAergic neurotransmission that function to increase GABA 
brain levels produce anxiolytic effects in rodent models of anxiety [71]. 
Chlordiazepoxide is an anxiolytic, GABA-enhancing agent, which, when given to 
BALB/c mice, produces several of the behavioural outcomes seen in this study. 
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Chlordiazepoxide administration in mice can lead to an increase in the time spent on 
the open arms of the elevated plus maze and lead to enhanced avoidance 
responses during active avoidance [72,73]. Repeated daily doses of 
chlordiazepoxide have also been shown to increase locomotion in the open field in 
BALB/c mice [74]. Although we did not measure functional changes in GABA 
receptors, it may be that the increased levels of GABA observed here were sufficient 
to produce the behavioural phenotype. It is also possible that the neurochemical 
changes could either be a direct consequence of vitamin D deficiency, or indirectly 
via altered baseline behaviour, such as altered locomotion in the home cage.  
There is little convergent evidence from three separate tests (EPM, holeboard, 
light/dark test) to suggest that AVD BALB/c mice had an anxiolytic phenotype. By 
contrast the evidence would suggest that the BALB/c AVD mice are more reactive, 
with enhanced open arm time on the EPM, greater ASR response, reduced latency 
to escape a footshock in the active avoidance, and reduced latency in the hot plate 
test. BALB/c mice typically freeze in response to aversive stimuli. The control 
BALB/c mice had difficulty responding in the active avoidance task. Instead of 
moving into the non-shocked compartment after the presentation of cues or foot-
shock, they froze in place, unable to move. The AVD-deficient BALB/c mice seemed 
able to overcome their natural freezing instinct to react by moving into the non-
shocked compartment on presentation of the stimulus, shortening their latency to 
escape over the length of the test when compared to controls. An increase in pain 
sensitivity could enhance the response to foot shock during avoidance learning and 
quicken their response in the hot plate test.  
We did not compare directly the effects of critical periods of vitamin D deficiency (i.e. 
gestational versus adult) in the current study. Data from developmental studies 
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indicates that a number of different mechanisms may exist by which vitamin D 
impacts both during brain development and on adult, from altered proliferation, 
apoptosis or mitosis [11]. There are no data on developmental vitamin D deficiency 
in BALB/c mice. We have published data to show that DVD C57BL/6 mice also show 
hyperlocomotion (Harms et al., 2008) and this would suggest that there may be a 
similar impact on the developing and adult brain. Comparisons between 
developmental and adult vitamin D deficiency in BALB/c mice would need to be 
carried out to address this question directly. In addition, the current findings were 
from male mice and these may not be generalizable to female mice and so these 
studies would also need to be performed.  
The results from the current study show that adult vitamin D deficiency has effects 
on behaviour and brain function in two inbred mouse strains. We found alterations 
consistent across both strains (hyperlocomotion and reduced GAD65/67) with many 
being altered only in the BALB/c strain, which was more susceptible to AVD than 
C57Bl/6. This suggests that our findings are not generaliseable to all mouse strains, 
although this is likely to be the case for many manipulations, for example 
environmental enrichment has strain specific effects on behaviour [75]. The current 
findings suggest that both excitatory and inhibitory neurotransmitter systems are 
affected by vitamin D deficiency in adult mice, which may be further exacerbated by 
the background strain or by detrimental environmental exposures or genomic 
instability. With vitamin D deficiency becoming increasingly recognised throughout 
the world [76,77], it is important to determine to what extent vitamin D deficiency 
contributes to adverse brain outcomes in light of the fact that supplementation is 
readily available. In particular, the findings seen in the AVD-deficient BALB/c mice 
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may provide a suitable tool for future investigations into the effects of vitamin D 
deficiency on the adult brain.  
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Figure 1. Behaviour in control and AVD-deficient C57BL/6J (a and c) and control and AVD-
deficient BALB/c (b and d) mice in the novel open field (n=28 per group a and b) andin the 
familiar open field (n=9-10 per group, c and d). In the novel open field arena, the AVD-
deficient mice from both the C57BL/6J and BALB/c strains showed significantly increased 
locomotion compared to controls. While, in the familiar open field the BALB/c AVD-deficient 
mice showed a significant reduction in locomotion when compared to controls, with no 
significant change in the C57BL/6J mice. p<0.05 (*), p<0.01 (**). 
Figure 2. Behaviour in control and AVD-deficient C57BL/6J (a and c) and control and AVD-
deficient BALB/c (b and d) mice on the elevated plus maze (n=8 per group, a and b) and 
acoustic startle response (n=20 per group, c and d). On the elevated plus maze, the BALB/c 
AVD-deficient mice spent significantly more time on the open arms when compared to 
control mice. In the acoustic startle response, BALB/c AVD-deficient mice had a significantly 
greater startle response than the control mice at pulse intensities of 90, 100, 110 and 120 
dB. p<0.01 (**). 
Figure 3. Behaviour in control and AVD-deficient C57BL/6J (a and c) and control and AVD-
deficient BALB/c (b and d) mice in the test of active avoidance (a and b), and on the hot plate 
test (c and d). In the test of active avoidance, the BALB/c AVD-deficient mice had a reduced 
latency to escape on Day 1 during acquisition, when compared to controls. On the hot plate 
test, the BALB/c AVD-deficient mice had a significantly shorter latency to link the hind paw 
when compared to the control mice, averaged over the 3 trials. p<0.05 (*), n=8 per group. 
Figure 4. Western Blots for GAD65/67 in control and AVD-deficient C57BL/6J (a) and control 
and AVD-deficient BALB/c (b) mice. There was a significant reduction in GAD65/67 for  AVD-
deficient mice compared to controls. Significance is noted as follows: <0.05 (*). A 
representative gel is shown in (c) which includes AVD-deficient samples (AVD) and control 
samples (Cont), n=8 per group.  
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Figure 5. Psychomimetic-induced hyperlocomotion in control and AVD-deficient C57BL/6J (a 
and c) and control and AVD-deficient BALB/c (b and d) mice in response to D-amphetamine 
(a and b), and MK-801 (c and d). The response to D-amphetamine was measured over 180 
min and while there was a significant difference in hyperlocomotion between strains, there 
was no significant effect of Diet. The response to MK-801 was measured over 210 mins and 
there was no significant effect of Diet or Strain on hyperlocomotion, n=8-10 per group. 
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Table 1. Mean (± SEM) levels for catecholamines and amino acids in brain tissue of 
control and AVD-deficient C57BL/6J and BALB/c mice.  
 C57BL/6J BALB/c 
(ng/g) Control AVD-deficient  Control AVD-deficient  
Catecholamines       
Noradrenaline  409.2 ± 4.7 387.6 ± 15.3  313.5 ± 18.8 349.2 ± 7.4  
Dihydroxyphenylacetic 
Acid  
111.7 ± 2.0 111.7 ± 4.1  113.5 ± 2.2 120.1 ± 2.7  
Dopamine  1122.3 ± 
23.5 
1093.6 ± 27.1  1120.6 ± 16.1 1134.7 ± 18.4  
5-hydroxy- 
indoleacetic Acid  
329.2 ± 8.7 388.0 ± 13.8 * 291.9 ± 13.9 311.3 ± 10.8  
Homovanillic Acid  187.9 ± 4.3 207.7 ± 8.0 * 197.3 ± 9.6 199.3 ± 5.9  
3-methoxytyramine  147.9 ± 5.2 150.6 ± 4.8  132.5 ± 4.7 132.3 ± 4.3  
5-hydroxytryptamine  557.1 ± 13.0 565.5 ± 9.1  507.7 ± 24.7 551.9 ± 12.3  
Amino acids       
Histidine  8.7 ± 1.7 12.2 ± 0.8  11.5 ± 2.3 15.2 ± 0.9  
Arginine  10.9 ± 1.5 10.7 ± 1.5  12.1 ± 0.9 13.6 ± 0.6  
Glutamine  659.9 ± 14.7 665.7 ± 56.2  712.2 ± 27.6 642.4 ± 14.8 * 
Serine  59.0 ± 0.8 67.7 ± 1.4 * 50.3 ± 2.8 58.7 ± 2.9  
Aspartic Acid  330.7 ± 13.7 346.7 ± 9.6  292.3 ± 33.7 289.6 ± 31.8  
Glutamate  1287.3 ± 
37.6 
1280.2 ± 27.6  1368.0 ± 39.1 1251.2 ± 22.6 * 
Glycine  54.6 ± 1.4 52.2 ± 1.3  36.4 ± 0.7 38.9 ± 0.7 * 
Taurine  1229.0 ± 
61.8 
1108.3 ± 39.4  1102.5 ± 40.5 1108.3 ± 24.0  
Lysine  53.1 ± 9.5 48.7 ± 5.7  38.9 ± 3.8 50.9 ± 2.6 * 
Tyrosine  14.1 ± 2.1 14.3 ± 2.0  6.5 ± 1.8 8.0 ± 2.0  
Alanine  28.3 ± 3.9 26.2 ± 5.6  26.8 ± 2.9 33.9 ± 5.0  
J-aminobutryic Acid  273.2 ± 11.6 273.2 ± 4.5  206.2 ± 5.4 223.9 ± 4.9 * 
Methionine  11.2 ± 0.3 10.9 ± 0.5  10.0 ± 0.4 10.0 ± 0.5  
* P<0.05 within strain comparison between control and AVD-deficient values. 
Table(s)
 
Table 2. A summary of the significant results found in the two strains of AVD-
deficient mice.  
 C57BL/6J AVD-deficient BALB/c AVD-deficient 
Behavioural Test Battery   
Novel Open Field U U 
Familiar Open Field − T 
Elevated Plus Maze − U 
Acoustic Startle Response 
Active Avoidance Aquisition 
− 
− 
U 
U 
Hot Plate Test − U 
Neurochemistry   
Glutamine − T 
Glutamate − T 
Glycine − U 
J-aminobutyric acid − U 
5-hydroxyindoleacetic acid U − 
Homovanillic acid U − 
Serine U − 
5-hydroxytryptamine: 5-hydroxy 
indoleacetic acid 
T − 
Dopamine: Homovanillic acid T − 
Proteins   
Glutamate decarboxylase 65/67 T T 
(U increased, T decreased, − no change). Experiments that had no change in 
either strain are omitted from this table (p = <0.05). 
 
